Medexus Pharmaceuticals (TSX:MDP) Change In Receivables : C$10.7 Mil (TTM As of Dec. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Medexus Pharmaceuticals Change In Receivables?

Medexus Pharmaceuticals's change in receivables for the quarter that ended in Dec. 2024 was C$-1.8 Mil. It means Medexus Pharmaceuticals's Accounts Receivable increased by C$1.8 Mil from Sep. 2024 to Dec. 2024 .

Medexus Pharmaceuticals's change in receivables for the fiscal year that ended in Mar. 2024 was C$-2.3 Mil. It means Medexus Pharmaceuticals's Accounts Receivable increased by C$2.3 Mil from Mar. 2023 to Mar. 2024 .

Medexus Pharmaceuticals's Accounts Receivable for the quarter that ended in Dec. 2024 was C$20.1 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Medexus Pharmaceuticals's Days Sales Outstanding for the three months ended in Dec. 2024 was 43.01.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Medexus Pharmaceuticals's liquidation value for the three months ended in Dec. 2024 was C$-109.5 Mil.

Medexus Pharmaceuticals Change In Receivables Historical Data

The historical data trend for Medexus Pharmaceuticals's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medexus Pharmaceuticals Change In Receivables Chart

Medexus Pharmaceuticals Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Change In Receivables

Get a 7-Day Free Trial

-10.80

-4.41

5.61

-11.27

-2.27

Medexus Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Change In Receivables	Get a 7-Day Free Trial															0.65	-2.56	14.72	0.34	-1.78

Medexus Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$10.7 Mil.

Medexus Pharmaceuticals (TSX:MDP) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Medexus Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	20.142	/	42.73	*	91
=	43.01

2. In Ben Graham's calculation of liquidation value, Medexus Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Medexus Pharmaceuticals's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	12.026	-	160.816	+	0.75 * 20.142	+	0.5 * 48.445
=	-109.5

Medexus Pharmaceuticals Change In Receivables Related Terms

Thank you for viewing the detailed overview of Medexus Pharmaceuticals's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Medexus Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Medexus Pharmaceuticals Inc (TSX:MDP) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

MEDXF:USA P731:Germany

Address

10 King Street East, Suite 600, Toronto, ON, CAN, M5C 1C3

Website

https://www.medexus.com

Medexus Pharmaceuticals Inc is a specialty pharmaceutical company with a powerful North American commercial platform and a growing portfolio of inventive and rare disease treatment solutions. The company's focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology.

Executives

Brendon Buschman	Senior Officer
Mike Mueller	Director
Benoit Gravel	Director
Stephen William Nelson	Director
Kenneth D'entremont	Director, Senior Officer
Marcel Pascal Konrad	Senior Officer
Brian Peters	Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Roland Boivin	Senior Officer
Michael Pine	Senior Officer
Glenn Tate	Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Richard Labelle	Senior Officer
Benoît Hébert	Senior Officer